ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 72 citations in OpenAlex.
- PPARG governs adipogenic differentiation and cell state plasticity in well-differentiated and dedifferentiated liposarcoma.Science advances · 2026Article
- Targeting eIF4A-dependent translation in genetically complex sarcoma.JCI insight · 2026Article
- Primary Dedifferentiated Liposarcoma of the Duodenum with Intestinal Bleeding: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2026Review
- Immunocompetent Murine Models Recapitulate the Heterogeneous Tumor-Immune Microenvironment of Human Liposarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Histologic Subvariants of Retroperitoneal Well-Differentiated Liposarcoma Show Evidence of Clinical and Genomic Progression Toward Dedifferentiated Liposarcoma.JCO precision oncology · 2025Article
- Copy number amplification of TTPAL promotes cholesterol biosynthesis and esophageal squamous cell carcinoma progression via elevating NSUN2-mediated m5C modification of SREBP2 mRNA.Journal of experimental & clinical cancer research : CR · 2025Article
- Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Five decades of sarcoma care at Memorial Sloan Kettering Cancer Center.Journal of surgical oncology · 2022Article
- Review
- Treatment Strategy for Elderly Patients with Soft Tissue Sarcoma.Current oncology reports · 2022Review
- Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.Human cell · 2022Article
- Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment.Journal of cancer research and clinical oncology · 2022Article
- A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- An original cuproptosis-related genes signature effectively influences the prognosis and immune status of head and neck squamous cell carcinoma.Frontiers in genetics · 2022Article
- Cytogenomic Characterization of Giant Ring or Rod Marker Chromosome in Four Cases of Well-Differentiated and Dedifferentiated Liposarcoma.Case reports in genetics · 2022Article
- Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma.Journal of personalized medicine · 2021Article
- Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.Human cell · 2021Article
- Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.Cancer research · 2020Article
- EI24 Inhibits Cell Proliferation and Drug Resistance of Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2020Article
- Integrated exome and RNA sequencing of dedifferentiated liposarcoma.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeMolecular events underlying progression of well-differentiated liposarcoma (WDLS) to dedifferentiated liposarcoma (DDLS) are poorly defined. This study sought to identify copy number alterations (CNA) associated with dedifferentiation of WDLS, with DDLS morphology, and with patient outcomes. EXPERIMENTAL
designFifty-five WDLS and 52 DDLS were analyzed using Agilent 244K comparative genomic hybridization and Affymetrix U133A expression arrays. CNAs were identified by RAE analysis. Thirty-nine of the DDLS specimens were categorized morphologically by a single pathologist.
resultsNine regions of CNA were identified as recurrent in DDLS but not WDLS; 79% of DDLS had at least one of these CNAs. Loss of the chromosome segment 11q23-24, the most common event, was observed only in DDLS that morphologically resembled the genomically complex sarcomas, undifferentiated pleomorphic sarcoma and myxofibrosarcoma. 11q23-24 loss was itself associated with increased genomic complexity in DDLS. Loss of 19q13, but not 11q23-24, was associated with poor prognosis. Median disease-specific survival was shorter for patients with19q13 loss (27 months) than for patients with diploid 19q13 (>90 months; P < 0.0025), and 19q13 loss was associated with local recurrence (HR, 2.86; P = 0.013). Common copy number losses were associated with transcriptional downregulation of potential tumor suppressors and adipogenesis-related genes (e.g., EI24 and CEBPA).
conclusionsDedifferentiation of WDLS is associated with recurrent CNAs in 79% of tumors. In DDLS, loss of 11q23-24 is associated with genomic complexity and distinct morphology whereas loss of 19q13 predicts poor prognosis. CNAs in liposarcoma improve risk stratification for patients and will help identify potential tumor suppressors driving liposarcoma progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.